Sagimet Biosciences Inc. Series A Common Stock (SGMT) — Strategic Asset Allocation Index
Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a Strategic Asset Allocation Index of 6.8% as of June 2026. Strategic assets (PP&E of $- plus long-term investments of $17.44 Million) total $17.44 Million, measured against net assets of $256.15 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Sagimet Biosciences Inc. Series A Common's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Sagimet Biosciences Inc. Series A Common Stock Strategic Asset Allocation Index (2023–2025)
This chart shows how Sagimet Biosciences Inc. Series A Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2023 to 2025. As of June 2026, the index stands at 6.8%, representing strategic assets of $17.44 Million against net assets of $256.15 Million USD. For live market cap and overall valuation, see Sagimet Biosciences Inc. Series A Common market cap and net worth.
Annual Strategic Asset Allocation Index for Sagimet Biosciences Inc. Series A Common Stock (2023–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Sagimet Biosciences Inc. Series A Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See net assets of Sagimet Biosciences Inc. Series A Common for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 0.0% | $0.00 | $- | $0.00 | $111.38 Million | ▼ -4.8 pp |
| 2024 | 4.8% | $7.41 Million | $- | $7.41 Million | $155.81 Million | ▲ +4.8 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $91.06 Million | — |